Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672801 · ClinicalTrials.gov registry record · NA
Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT
A NA study, sponsored by Boston IVF.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01672801 is a NA study that has completed, run by Boston IVF. The registered enrollment target is 18 participants.
The verdict
NCT01672801, a NA study, has completed, sponsored by Boston IVF.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the effectiveness of nimodipine in preventing a luteinizing hormone (LH) surge in women undergoing ovulation induction with clomiphene citrate. It is important to prevent the premature LH surge in controlled ovarian stimulation to allow adequate recruitment of follicles, proper maturation of a dominant follicle before ovulation, and effectively time insemination with semen to allow fertilization of a mature egg to occur. The investigators are also conducting this study to determine medication side effect profile (including lightheadedness or dizziness from low blood pressure or rapid heart rate, headache, and nausea), patient treatment compliance, and clinical pregnancy (positive pregnancy test and ultrasound evidence of fetal heart rate). Finally, LH and follicle stimulating hormone (FSH) serum levels will be measured to determine effect of nimodipine on these hormones. As a calcium channel blocker, nimodipine has been shown to block calcium mediated release of gonadotropin releasing hormone in animal and preliminary human studies. The investigators hypothesize that nimodipine, a calcium channel blocker, will prevent or delay the LH surge during controlled ovarian stimulation cycles using clomiphene citrate in subfertile patients undergoing assisted reproduction with intrauterine insemination (IUI).
Interventions
- DRUG Placebo
- DRUG Nimodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672801
The ClinicalTrials.gov registry entry for NCT01672801 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston IVF, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01672801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672801 about?
NCT01672801 is a clinical study titled "Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT". The main purpose of this study is to test the effectiveness of nimodipine in preventing a luteinizing hormone (LH) surge in women undergoing ovulation induction with clomiphene citrate. It is important to prevent the premature LH surge in controlled ovarian stimulation to allow adequate recruitment ...
What is the current status of trial NCT01672801?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2012-09. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01672801?
The interventions under investigation include: Placebo (DRUG), Nimodipine (DRUG).
Who is sponsoring clinical trial NCT01672801?
This trial is sponsored by Boston IVF, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.